Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Helminth driven gut inflammation and microbial translocation associate with altered vaccine responses in rural Uganda.
Nassuuna, J; Sterk, J; Walusimbi, B; Natukunda, A; Nkangi, R; Amongin, R; ZIRIMENYA, L; WEBB, EL; ELLIOTT, AM; NKURUNUNGI, G;
2025
NPJ Vaccines, (2025).10 1 10.1038/s41541-025-01116-x.
Isoniazid preventive therapy modulates Mycobacterium tuberculosis-specific T-cell responses in individuals with latent tuberculosis and type 2 diabetes.
Ssekamatte, P; SITENDA, D; Nabatanzi, R; Nakibuule, M; Kibirige, D; Kyazze, AP; Kateete, DP; Bagaya, BS; Sande, OJ; Van Crevel, R; COSE, S; Biraro, IA;
2025
Scientific reports, (2025).15 1 10.1038/s41598-025-95386-z.
Thinking fast and slow: the urgency of crisis response must not lead us to overlook chronic needs such as tuberculosis.
Dodd, PJ; VAN ZANDVOORT, K; CHECCHI, F; Khan, U; Haqmal, M; KHAN, P; MCQUAID, CF;
2025
BMJ global health, (2025).10 3 10.1136/bmjgh-2024-018012.
Population impact of new TB vaccines may depend on efficacy against infectious asymptomatic TB: a modelling study.
TANVIR, H; CLARK, R; SUMNER, T; HORTON, K; Prŷs-Jones, T; Bakker, R; Rade, K; Mave, V; Hatherill, M; Churchyard, G; HOUBEN, RM G J; WHITE, R;
2025
medRxiv (2025). 10.1101/2025.03.24.25323816.
Tuberculosis preventive therapy: scientific and ethical considerations for trials of ultra-short regimens.
Walker, TM; Watson, JA; MOORE, DA J; Frick, M; Jamrozik, E;
2025
The Lancet. Infectious diseases, (2025).25 7 10.1016/S1473-3099(25)00083-0.
IgG antibody response to Mycobacterium tuberculosis curli pili (MTP) in people from different geographical regions in Sub-Saharan Africa.
Pillay, K; Coetzer, T; Connolly, C; Pillay, B; Chiliza, T; Naidoo, K; SUTHERLAND, J; Ndung'u, T; Mayanja-Kizza, H; Pillay, M;
2025
Tuberculosis (Edinburgh, Scotland), (2025).152, 10.1016/j.tube.2025.102634.
Plasma proteomics for novel biomarker discovery in childhood tuberculosis.
Fossati, A; Wambi, P; Jaganath, D; Calderon, R; Castro, R; Mohapatra, A; McKetney, J; Luiz, J; Nerurkar, R; NKEREUWEM, E; Franke, MF; Mousavian, Z; Collins, JM; Sigal, GB; Segal, MR; Kampman, B; Wobudeya, E; Cattamanchi, A; Ernst, JD; Zar, HJ; Swaney, DL;
2025
medRxiv (2025). 10.1101/2024.12.05.24318340.
A roadmap for integrating nutritional assessment, counselling, and support into the care of people with tuberculosis.
Sinha, P; Bhargava, M; Carwile, ME; Dauphinais, MR; Tisile, P; Cintron, C; Locks, LM; Hauser, J; Oliver, M; Heysell, SK; Mehta, S; Finkelstein, JL; Koura, KG; Cegielski, JP; HOUBEN, RM G J; MCQUAID, CF; Bhargava, A;
2025
The Lancet. Global health, (2025).13 5 10.1016/S2214-109X(25)00021-X.
World TB Day 2025 Theme "Yes! We Can End TB: Commit, Invest, Deliver" can be made a reality through concerted global efforts to advance diagnosis, treatment and research of tuberculosis infection and disease.
Goletti, D; Matteelli, A; CLIFF, JM; Meintjes, G; Graham, S; Esmail, H; Shan Lee, S;
2025
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, (2025).155, 10.1016/j.ijid.2025.107892.
Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes.
Yates, TA; GRINT, DJ;
2025
The Lancet microbe, (2025).6 7 10.1016/j.lanmic.2025.101117.